Green tea derived EGCG opposes AIDS dementia-like neuronal damage

绿茶提取的 EGCG 可以对抗艾滋病痴呆样神经元损伤

基本信息

  • 批准号:
    7460708
  • 负责人:
  • 金额:
    $ 18.38万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2007
  • 资助国家:
    美国
  • 起止时间:
    2007-07-05 至 2011-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Our long term goal is to develop effective agents for AIDS dementia complex. The purpose of this project is to investigate if green tea EGCG, a known inhibitor of signal transducer and activation of transcription 1 (STAT1), could attenuate AIDS-like neuronal damage through disruption STAT1 signaling in mice exposed to IFN-g with HIV-1 proteins gp120 and Tat. A state of immune activation characterized by increased levels of pro-inflammatory cytokines is widely regarded as an important factor leading to AIDS dementia-like neuronal damage and a key regulator for pro-inflammatory signaling in neurons is STAT1. STAT1 activation is involved in neuronal injury/death associated with brain ischemia, as well as AIDS dementia. Moreover its "activator" IFN-g, has been shown to be elevated both in the cerebrospinal fluid and brains of HIV positive individuals. Results from our pilot studies suggest that IFN-g enhances the neurotoxic effects of gp120 and Tat. Further, AIDS dementia-like neuronal damage from this combined insult was largely attenuated in STAT1 deficient neurons. We and others have shown that the treatment of primary neurons with EGCG reduces STAT1 activation and resultant neuronal injury in models of AIDS dementia and stroke, respectively. We hypothesize that EGCG treatment will decrease AIDS dementia-like neuronal damage via STAT1 suppression. Aim 1 is to establish a mouse model representative of the possible neuronal damage exhibited in AIDS dementia. Aim 2 will characterize the role of STAT1 in mediating neuronal injury induced by IFN-g and gp120 and Tat in mice. To this end we will compare the neuronal damage in STAT1 deficient mice to control mice after intracerebroventricular injection of IFN-g with gp120 or Tat. We expect STAT1 deficient mice will show a marked decrease in AIDS dementia-like neuronal damage compared to control. Aim 3 will investigate the effects of EGCG on inhibition of the neuronal damage resulting from IFN-g mediated STAT1 activation in the presence of gp120 or Tat in mice. Here we also plan to delineate the most effective EGCG intraperitoneal injection by comparing AIDS dementia-like neuronal damage in prophylactic, therapeutic, and combined prophylactic/therapeutic paradigms. We hypothesize that EGCG-treated mice will show significant decreases in AIDS dementia-like neuronal damage when compared to vehicle-treated mice. These data should lay the foundation for further research leading to human trials in the near future. Narrative: The purpose of this project is to investigate if green tea derived EGCG could attenuate AIDS-like neuronal damage in the mouse model. We hypothesize that EGCG-treated mice will show significant decreases in AIDS dementia-like neuronal damage when compared to vehicle-treated mice. These data should lay the foundation for further research leading to human trials in the near future.
描述(申请人提供):我们的长期目标是开发有效的治疗艾滋病痴呆症的药物。本项目的目的是研究绿茶EGCG,一种已知的信号转导和转录激活1(STAT1)的抑制剂,是否可以通过干扰信号转导和转录激活1(STAT1)信号来减轻暴露于带有HIV-1蛋白gp120和TAT的干扰素-g的小鼠的艾滋病样神经元损伤。以促炎细胞因子水平升高为特征的免疫激活状态被广泛认为是导致艾滋病痴呆样神经元损伤的重要因素,而神经元中促炎信号的关键调节因子是STAT1。STAT1的激活参与了与脑缺血和艾滋病痴呆相关的神经元损伤/死亡。此外,它的“激活物”干扰素-g已被证明在艾滋病毒阳性者的脑脊液和大脑中都升高。我们的初步研究结果表明,干扰素-g增强了gp120和Tat的神经毒性作用。此外,在STAT1缺乏的神经元中,这种联合侮辱造成的艾滋病痴呆样神经元损伤在很大程度上得到了减轻。我们和其他人已经证明,在艾滋病痴呆和中风模型中,EGCG治疗初级神经元分别减少了STAT1的激活和由此导致的神经元损伤。我们假设EGCG治疗将通过抑制STAT1减少艾滋病痴呆样神经元损伤。目的1是建立一个代表艾滋病痴呆可能表现出的神经元损伤的小鼠模型。目的2研究STAT1在干扰素-g、gp120和TAT诱导的小鼠神经元损伤中的作用。为此,我们将比较STAT1缺陷小鼠和对照组小鼠在脑室注射干扰素-g与gp120或Tat后的神经元损伤。我们预计,与对照组相比,STAT1缺陷小鼠的艾滋病痴呆样神经元损伤将显着减少。目的研究EGCG对gp120或Tat诱导的干扰素-g介导的STAT1激活所致的小鼠神经元损伤的抑制作用。在这里,我们还计划通过比较预防、治疗和联合预防/治疗方案中的艾滋病痴呆样神经元损伤来描述最有效的EGCG腹腔注射。我们假设,与赋形剂治疗的小鼠相比,EGCG治疗的小鼠将显着减少艾滋病痴呆样神经元损伤。这些数据应该会为在不久的将来进行人体试验的进一步研究奠定基础。说明:该项目的目的是调查绿茶提取的EGCG是否可以减轻小鼠模型中艾滋病样神经元的损伤。我们假设,与赋形剂治疗的小鼠相比,EGCG治疗的小鼠将显着减少艾滋病痴呆样神经元损伤。这些数据应该会为在不久的将来进行人体试验的进一步研究奠定基础。

项目成果

期刊论文数量(5)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Psychiatric implications of hepatitis-C infection.
丙型肝炎感染的精神影响。
  • DOI:
    10.1615/critrevneurobiol.v19.i2-3.20
  • 发表时间:
    2007
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Giunta,Brian;Somboonwit,Charurut;Nikolic,WilliamV;Rrapo,Elona;Tan,Jun;Shapshak,Paul;Fernandez,Francisco
  • 通讯作者:
    Fernandez,Francisco
Antiretroviral medications disrupt microglial phagocytosis of β-amyloid and increase its production by neurons: implications for HIV-associated neurocognitive disorders.
  • DOI:
    10.1186/1756-6606-4-23
  • 发表时间:
    2011-06-07
  • 期刊:
  • 影响因子:
    3.6
  • 作者:
    Giunta B;Ehrhart J;Obregon DF;Lam L;Le L;Jin J;Fernandez F;Tan J;Shytle RD
  • 通讯作者:
    Shytle RD
HIV-1 Tat-induced microglial activation and neuronal damage is inhibited via CD45 modulation: A potential new treatment target for HAND.
HIV-1 Tat 诱导的小胶质细胞激活和神经元损伤通过 CD45 调节受到抑制:HAND 的潜在新治疗靶点。
HIV-1 TAT inhibits microglial phagocytosis of Abeta peptide.
Efavirenz promotes β-secretase expression and increased Aβ1-40,42 via oxidative stress and reduced microglial phagocytosis: implications for HIV associated neurocognitive disorders (HAND).
  • DOI:
    10.1371/journal.pone.0095500
  • 发表时间:
    2014
  • 期刊:
  • 影响因子:
    3.7
  • 作者:
    Brown LA;Jin J;Ferrell D;Sadic E;Obregon D;Smith AJ;Tan J;Giunta B
  • 通讯作者:
    Giunta B
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jun Tan其他文献

Jun Tan的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jun Tan', 18)}}的其他基金

Identification of novel APP-specific alpha secretase in human umbilical cord blood sera
人脐带血血清中新型 APP 特异性 α 分泌酶的鉴定
  • 批准号:
    9380529
  • 财政年份:
    2017
  • 资助金额:
    $ 18.38万
  • 项目类别:
A flavonoid gamma-secretase modulator (GSM) reduces beta-amyloid and tau pathologies in the AD mice
类黄酮 γ 分泌酶调节剂 (GSM) 可减少 AD 小鼠的 β-淀粉样蛋白和 tau 蛋白病理
  • 批准号:
    9127058
  • 财政年份:
    2015
  • 资助金额:
    $ 18.38万
  • 项目类别:
A flavonoid gamma-secretase modulator (GSM) reduces beta-amyloid and tau pathologies in the AD mice
类黄酮 γ 分泌酶调节剂 (GSM) 可减少 AD 小鼠的 β-淀粉样蛋白和 tau 蛋白病理
  • 批准号:
    8976888
  • 财政年份:
    2015
  • 资助金额:
    $ 18.38万
  • 项目类别:
Flavonoid-diosmin modulation of Abeta and tau pathologies through GSK-3 signaling
类黄酮-地奥司明通过 GSK-3 信号传导调节 Abeta 和 tau 病理学
  • 批准号:
    8627446
  • 财政年份:
    2014
  • 资助金额:
    $ 18.38万
  • 项目类别:
Octyl gallate (OG) and Promotion of non-amyloidogenic processing of APP
没食子酸辛酯 (OG) 和促进 APP 的非淀粉样蛋白加工
  • 批准号:
    8803251
  • 财政年份:
    2013
  • 资助金额:
    $ 18.38万
  • 项目类别:
Octyl gallate (OG) and Promotion of non-amyloidogenic processing of APP
没食子酸辛酯 (OG) 和促进 APP 的非淀粉样蛋白加工
  • 批准号:
    8441038
  • 财政年份:
    2013
  • 资助金额:
    $ 18.38万
  • 项目类别:
IL-6-mediated Jak2/Stat3 signaling and Brain Development
IL-6 介导的 Jak2/Stat3 信号传导与大脑发育
  • 批准号:
    7985709
  • 财政年份:
    2010
  • 资助金额:
    $ 18.38万
  • 项目类别:
IL-6-mediated Jak2/Stat3 signaling and Brain Development
IL-6 介导的 Jak2/Stat3 信号传导与大脑发育
  • 批准号:
    8135535
  • 财政年份:
    2010
  • 资助金额:
    $ 18.38万
  • 项目类别:
Implication of HUCBC: a novel therapeutic strategy for Alzheimer's disease
HUCBC 的意义:阿尔茨海默病的一种新治疗策略
  • 批准号:
    8505320
  • 财政年份:
    2009
  • 资助金额:
    $ 18.38万
  • 项目类别:
Implication of HUCBC: a novel therapeutic strategy for Alzheimer's disease
HUCBC 的意义:阿尔茨海默病的一种新治疗策略
  • 批准号:
    8305549
  • 财政年份:
    2009
  • 资助金额:
    $ 18.38万
  • 项目类别:

相似海外基金

A platform for rapidly generating live attenuated enterovirus vaccines
快速生成减毒肠道病毒活疫苗的平台
  • 批准号:
    24K02286
  • 财政年份:
    2024
  • 资助金额:
    $ 18.38万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
I-Corps: Translation potential of an efficient method to generate live-attenuated and replication-defective DNA viruses for vaccine development
I-Corps:一种有效方法的转化潜力,可生成用于疫苗开发的减毒活病毒和复制缺陷型 DNA 病毒
  • 批准号:
    2420924
  • 财政年份:
    2024
  • 资助金额:
    $ 18.38万
  • 项目类别:
    Standard Grant
Developing a robust native extracellular matrix to improve islet function with attenuated immunogenicity for transplantation
开发强大的天然细胞外基质,以改善胰岛功能,并减弱移植的免疫原性
  • 批准号:
    10596047
  • 财政年份:
    2023
  • 资助金额:
    $ 18.38万
  • 项目类别:
Live attenuated non-transmissible (LANT) Klebsiella pneumoniae vaccines
肺炎克雷伯氏菌减毒非传染性 (LANT) 活疫苗
  • 批准号:
    10742028
  • 财政年份:
    2023
  • 资助金额:
    $ 18.38万
  • 项目类别:
Protecting Pigs From Enzootic Pneumonia: Rational Design Of Safe Attenuated Vaccines.
保护猪免受地方性肺炎:安全减毒疫苗的合理设计。
  • 批准号:
    BB/X017540/1
  • 财政年份:
    2023
  • 资助金额:
    $ 18.38万
  • 项目类别:
    Research Grant
A “Goldilocks” live attenuated poultry vaccine for Infectious Coryza
用于传染性鼻炎的“Goldilocks”家禽减毒活疫苗
  • 批准号:
    LP210301365
  • 财政年份:
    2023
  • 资助金额:
    $ 18.38万
  • 项目类别:
    Linkage Projects
A novel live-attenuated Zika vaccine with a modified 5'UTR
一种带有改良 5UTR 的新型寨卡减毒活疫苗
  • 批准号:
    10730832
  • 财政年份:
    2023
  • 资助金额:
    $ 18.38万
  • 项目类别:
Combating melanoma with an attenuated bacterial therapeutic
用减毒细菌疗法对抗黑色素瘤
  • 批准号:
    10659841
  • 财政年份:
    2023
  • 资助金额:
    $ 18.38万
  • 项目类别:
L2M NSERC-Bioengineering attenuated Sclerotinia sclerotiorum strains as bioherbicide for cereal production and lawn management
L2M NSERC-生物工程减毒核盘菌菌株作为谷物生产和草坪管理的生物除草剂
  • 批准号:
    576545-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 18.38万
  • 项目类别:
    Idea to Innovation
Investigating Host and Viral Factors for Improved Design of Future Live Attenuated Vaccines for IBV
研究宿主和病毒因素以改进未来 IBV 减毒活疫苗的设计
  • 批准号:
    BB/V016067/1
  • 财政年份:
    2022
  • 资助金额:
    $ 18.38万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了